<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016016</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-03153</org_study_id>
    <secondary_id>NCI-2012-03153</secondary_id>
    <secondary_id>MSGCC-0052</secondary_id>
    <secondary_id>NCI-3170</secondary_id>
    <secondary_id>JHOC-J0254</secondary_id>
    <secondary_id>J0254</secondary_id>
    <secondary_id>3170</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <secondary_id>U01CA069854</secondary_id>
    <nct_id>NCT00016016</nct_id>
  </id_info>
  <brief_title>Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia</brief_title>
  <official_title>A Phase I/II Study of Flavopiridol (NSC 649890, IND 46,211) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Poor-Risk Acute Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of combining flavopiridol and cytarabine with&#xD;
      mitoxantrone in treating patients who have acute leukemia. Drugs used in chemotherapy work in&#xD;
      different ways to stop cancer cells from dividing so they stop growing or die. Combining more&#xD;
      than one drug may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the toxicities of escalating doses of flavopiridol administered in a timed&#xD;
      sequence with ara-C and mitoxantrone in adults with refractory or relapsed acute leukemias or&#xD;
      high-risk myelodysplasias (MDS).&#xD;
&#xD;
      II. To determine if flavopiridol administered in a timed sequence with ara-C and Mitoxantrone&#xD;
      will induce clinical responses in adults with refractory or relapsed acute leukemias or MDS.&#xD;
&#xD;
      III. To determine if flavopiridol is directly cytotoxic to leukemic blasts in vivo.&#xD;
&#xD;
      IV. To determine if flavopiridol can recruit and synchronize residual leukemic blasts to&#xD;
      proliferate in vivo.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of flavopiridol. (Phase I closed to accrual&#xD;
      effective10/24/2003).&#xD;
&#xD;
      Patients receive flavopiridol IV over 1 hour on days 1-3 and cytarabine IV continuously on&#xD;
      days 6-9 followed by mitoxantrone IV over 30-150 minutes on day 9. Patients achieving a&#xD;
      partial or complete response after the first course of therapy may receive an additional&#xD;
      course of therapy beginning 35 ± 7 days after blood count recovery.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity. (Phase I closed to accrual&#xD;
      effective 10/24/2003). Once the MTD is reached, additional patients are accrued to receive&#xD;
      flavopiridol at the recommended phase II dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) as assessed by NCI CTC version 2.0</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission (CR)</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Untreated Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (flavopiridol, cytarabine, mitoxantrone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive flavopiridol IV over 1 hour on days 1-3 and cytarabine IV continuously on days 6-9 followed by mitoxantrone IV over 30-150 minutes on day 9. Patients achieving a partial or complete response after the first course of therapy may receive an additional course of therapy beginning 35 ± 7 days after blood count recovery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (flavopiridol, cytarabine, mitoxantrone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (flavopiridol, cytarabine, mitoxantrone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (flavopiridol, cytarabine, mitoxantrone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (flavopiridol, cytarabine, mitoxantrone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory procedure</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (flavopiridol, cytarabine, mitoxantrone)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Established diagnoses of poor-risk hematologic malignancies will be considered&#xD;
             eligible for this Phase I/II study&#xD;
&#xD;
          -  Pathological confirmation of the diagnosis of AML or ALL&#xD;
&#xD;
          -  ECOG performance status 0,1,2&#xD;
&#xD;
          -  Patients must be able to give informed consent&#xD;
&#xD;
          -  Female patients of childbearing age must have negative pregnancy test&#xD;
&#xD;
          -  AST and ALT =&lt; 2.5 x normal&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 2.5 x normal&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 x normal&#xD;
&#xD;
          -  Serum creatinine =&lt; 2.0 mg/dl&#xD;
&#xD;
          -  Left ventricular ejection fraction must &gt;= 45% by MUGA or Echocardiogram&#xD;
&#xD;
          -  Acute Myelogenous Leukemia (AML)&#xD;
&#xD;
               -  AML arising from MDS&#xD;
&#xD;
               -  Secondary AML&#xD;
&#xD;
               -  Relapsed or refractory AML, including primary induction failure&#xD;
&#xD;
          -  Acute Lymphoblastic Leukemia (ALL)&#xD;
&#xD;
               -  Relapsed or refractory ALL, including primary induction failure&#xD;
&#xD;
               -  Patients who fail primary induction therapy or who relapse after achieving&#xD;
                  complete remission (CR) are eligible if they have undergone no more than 3 prior&#xD;
                  courses of induction/reinduction&#xD;
&#xD;
          -  There should be an interval of at least 4 weeks from any previous intensive&#xD;
             chemotherapy before beginning flavopiridol, with the exceptions non-aplasia producing&#xD;
             treatments (i.e. hydroxyurea, interferon, imatinib, 6MP, thalidomide); patients should&#xD;
             have recovered completely from any treatment-related toxicities; patients may have&#xD;
             received hematopoietic growth factors previously, but must be off all growth factors&#xD;
             (including EPO, G-CSF, GM-CSF, IL-3, IL-11) for at least 4 days prior to beginning&#xD;
             flavopiridol&#xD;
&#xD;
          -  Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic,&#xD;
             are eligible provided that they are &gt;= 4 weeks from stem cell infusion, have no active&#xD;
             GVHD, and meet other eligibility criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hyperleukocytosis with &gt;= 50,000 leukemic blasts/mm^3&#xD;
&#xD;
          -  Active, uncontrolled infection&#xD;
&#xD;
          -  Disseminated intravascular coagulation&#xD;
&#xD;
          -  Active CNS leukemia&#xD;
&#xD;
          -  Concomitant chemotherapy, radiation therapy or immunotherapy&#xD;
&#xD;
          -  Intrinsic impaired cardiac function (MI within the preceding 3 months or history of&#xD;
             severe coronary artery disease, cardiomyopathy, CHF &gt; Class II)&#xD;
&#xD;
          -  History of congestive heart disease, or arrhythmia without regard to time, severity or&#xD;
             resolution&#xD;
&#xD;
          -  Women who are pregnant or lactating will not be eligible for this trial, as the&#xD;
             investigational agent may be harmful to the developing fetus or nursing infant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Karp</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-8936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 7, 2013</last_update_submitted>
  <last_update_submitted_qc>October 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

